FDA Orange Book · active-ingredient family
Abametapir
Abametapir is approved in 1 FDA application, with therapeutic-equivalence codes, listed patents, and marketing exclusivity from the FDA Orange Book.
Reference-listed drug:XEGLYZE · NDA 206966
1
Brand (NDA)
0
Generics (ANDA)
2
Listed patents
0
Exclusivity periods
Brand (NDA) products · lotion
| Product | Applicant | Application | TE | Approved | |
|---|---|---|---|---|---|
| XEGLYZERLD | LNHC | NDA 206966 | — | Jul 24, 2020 |
Listed patents (2)
| Patent | Expires | In | Type |
|---|---|---|---|
| 7812163 | Oct 28, 2026 | in 4 mo | ProductU-2863 |
| 10292389 | Dec 17, 2034 | in 8 yr 7 mo | ProductU-2863 |
Abametapir — frequently asked questions
Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.
